CN101578295B - 与胰腺导管腺癌相关的新型抗原和抗体 - Google Patents

与胰腺导管腺癌相关的新型抗原和抗体 Download PDF

Info

Publication number
CN101578295B
CN101578295B CN2007800423663A CN200780042366A CN101578295B CN 101578295 B CN101578295 B CN 101578295B CN 2007800423663 A CN2007800423663 A CN 2007800423663A CN 200780042366 A CN200780042366 A CN 200780042366A CN 101578295 B CN101578295 B CN 101578295B
Authority
CN
China
Prior art keywords
pda
antibodies
enolase
enoa
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800423663A
Other languages
English (en)
Chinese (zh)
Other versions
CN101578295A (zh
Inventor
弗朗切斯科·诺韦利
芭芭拉·托马伊诺
保拉·卡佩洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribovax Biotechnologies SA
Bioline Diagnostici SRL
Original Assignee
Ribovax Biotechnologies SA
Bioline Diagnostici SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies SA, Bioline Diagnostici SRL filed Critical Ribovax Biotechnologies SA
Publication of CN101578295A publication Critical patent/CN101578295A/zh
Application granted granted Critical
Publication of CN101578295B publication Critical patent/CN101578295B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2007800423663A 2006-09-29 2007-09-28 与胰腺导管腺癌相关的新型抗原和抗体 Expired - Fee Related CN101578295B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06121552 2006-09-29
EP06121552.1 2006-09-29
EP06126726 2006-12-20
EP06126726.6 2006-12-20
PCT/EP2007/060305 WO2008037792A1 (en) 2006-09-29 2007-09-28 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma

Publications (2)

Publication Number Publication Date
CN101578295A CN101578295A (zh) 2009-11-11
CN101578295B true CN101578295B (zh) 2013-02-27

Family

ID=38895810

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800423663A Expired - Fee Related CN101578295B (zh) 2006-09-29 2007-09-28 与胰腺导管腺癌相关的新型抗原和抗体

Country Status (18)

Country Link
US (1) US8071721B2 (enExample)
EP (1) EP2069395B1 (enExample)
JP (1) JP2010505104A (enExample)
KR (1) KR20090094227A (enExample)
CN (1) CN101578295B (enExample)
AT (1) ATE542831T1 (enExample)
AU (1) AU2007301966B2 (enExample)
BR (1) BRPI0717282A2 (enExample)
CA (1) CA2664841A1 (enExample)
DK (1) DK2069395T3 (enExample)
EA (1) EA016731B1 (enExample)
ES (1) ES2381304T3 (enExample)
IL (2) IL197868A (enExample)
NO (1) NO20091662L (enExample)
NZ (1) NZ576409A (enExample)
PL (1) PL2069395T3 (enExample)
PT (1) PT2069395E (enExample)
WO (1) WO2008037792A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171569A (zh) * 2008-05-09 2011-08-31 杜克大学 检测和治疗癌症的自身抗体
IT1398782B1 (it) 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
ITTO20120523A1 (it) * 2012-06-15 2013-12-16 Natimab Therapeutics S R L Procedimento e kit per la diagnosi in vitro dell'adenocarcinoma duttale pancreatico o per determinare la predisposizione all'adenocarcinoma duttale pancreatico
CA2949045C (en) * 2013-12-20 2022-07-05 Development Center For Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
EP3094341B1 (en) 2014-01-13 2019-10-02 Berg LLC Enolase 1 (eno1) compositions and uses thereof
CN115786317B (zh) * 2022-12-12 2026-03-20 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARCUS K ET AL.IDENTIFICATION OF PLATELET PROTEINS SEPARATED BY TWO-DIMENSIONAL GEL ELECTROPHORESIS AND ANALYZED BY MATRIX ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT-MASS SPECTROMETRY AND DETECTION OF TYROSINEPHOSPHORYLATED PROTEINS.《ELECTROPHORESIS》.2000,第21卷(第13期),第2622-2636页. *
SHEN JIANJUN ET AL.Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry.《CANCER RESEARCH》.2004,第64卷(第24期),第9018-9026页. *
TANAKA MINORU ET AL.Chicken alpha-enolase by not beta-enolase has a Src-dependent tyrosine-phosphorylation site: cDNA cloning and nucleotide sequence analysis.《JOURNAL OF BIOCHEMISTRY》.1995,第117卷(第3期),第554-559页. *

Also Published As

Publication number Publication date
AU2007301966A1 (en) 2008-04-03
PT2069395E (pt) 2012-04-27
EA200970332A1 (ru) 2009-10-30
EP2069395B1 (en) 2012-01-25
US20100028907A1 (en) 2010-02-04
JP2010505104A (ja) 2010-02-18
AU2007301966B2 (en) 2013-02-21
IL197868A (en) 2013-03-24
PL2069395T3 (pl) 2012-06-29
EA016731B1 (ru) 2012-07-30
DK2069395T3 (da) 2012-05-14
WO2008037792A1 (en) 2008-04-03
ES2381304T3 (es) 2012-05-25
US8071721B2 (en) 2011-12-06
IL218442A0 (en) 2012-04-30
NZ576409A (en) 2012-02-24
CA2664841A1 (en) 2008-04-03
EP2069395A1 (en) 2009-06-17
BRPI0717282A2 (pt) 2013-10-15
ATE542831T1 (de) 2012-02-15
IL197868A0 (en) 2011-08-01
NO20091662L (no) 2009-06-29
CN101578295A (zh) 2009-11-11
KR20090094227A (ko) 2009-09-04

Similar Documents

Publication Publication Date Title
CN101578295B (zh) 与胰腺导管腺癌相关的新型抗原和抗体
EP2553458A2 (en) Serum and tissue biomarkers of human hcc
Shiozaki et al. Phosphatidic acid‐mediated activation and translocation to the cell surface of sialidase NEU3, promoting signaling for cell migration
Di Pisa et al. SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates migration in the MDA-MB-231 cell line
Sheng et al. SENP1-mediated deSUMOylation of YBX1 promotes colorectal cancer development through the SENP1-YBX1-AKT signaling axis
Zhang et al. Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA
EP3042203B1 (en) Biomarkers for cholangiocellular carcinoma (ccc)
JP7546255B2 (ja) 癌を検出する方法および検出試薬
Chaudhary et al. Exposure of a specific pleioform of multifunctional glyceraldehyde 3-phosphate dehydrogenase initiates CD14-dependent clearance of apoptotic cells
Zaragozá et al. Nitration of cathepsin D enhances its proteolytic activity during mammary gland remodelling after lactation
WO2010071788A1 (en) Pancreatic cancer markers and uses thereof
Lončar-Brzak et al. Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential
CA2909474C (en) New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation
Azuma et al. Identification of sialylated glycoproteins in Doxorubicin-treated hepatoma cells with glycoproteomic analyses
Chu et al. Human cancer cells retain modest levels of enzymatically active matriptase only in extracellular milieu following induction of zymogen activation
Li et al. Clinical significance and functional validation of inorganic pyrophosphatase in diffuse large B cell lymphoma in humans
Zhang et al. Comparative analysis of the human urinary proteome by 1D SDS-PAGE and chip-HPLC-MS/MS identification of the AACT putative urinary biomarker
Thakar et al. SUMOylation of the hepatoma‐derived growth factor negatively influences its binding to chromatin
Ye et al. Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics
Saar-Kovrov et al. Protein carbamylation in atherosclerotic plaques correlates with uremia and disease progression, localizing predominantly to foam cells
Yan et al. High-expressing cystic fibrosis transmembrane conductance regulator interacts with histone deacetylase 2 to promote the development of Ph+ leukemia through the HDAC2-mediated PTEN pathway
Dziadosz-Brzezińska et al. Considerations for antibody-based detection of NRF2 in human cells
Postic et al. Over‐expression of Dyrk1A affects bleeding by modulating plasma fibronectin and fibrinogen level in mice
Miranda et al. Heterologous expression of Homo sapiens alpha-folate receptors in E. coli by fusion with a trigger factor for enhanced solubilization
Akyildiz Demir et al. Identification of cytoplasmic sialidase NEU2-associated proteins by LC-MS/MS

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130227

Termination date: 20170928

CF01 Termination of patent right due to non-payment of annual fee